Cocrystal Pharma soars as FDA fast-tracks oral norovirus drug

Cocrystal Pharma

02/04/2026 16:27

Updates

** Shares of drug developer Cocrystal Pharma COCP.O soar 42% to $1.44

** Co says FDA grants fast-track status to its experimental oral drug CDI-988 for norovirus, a highly contagious stomach virus that causes vomiting and diarrhea; no approved treatments exist

** CDI-988 is being tested in an early-stage study in up to 40 healthy adults to reduce norovirus symptoms and assess safety and how the drug moves through the body, co says

** Says norovirus hits immunocompromised patients hardest, often causing long-term infections

** Fast-track status aims to speed development and review for drugs addressing serious diseases with unmet medical needs

** Including session move, stock up ~4% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))